Product Description
Mechanisms of Action: ELA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | Korea
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Lung Injury|Acute Respiratory Distress Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20210072 | P1 |
Recruiting |
Acute Lung Injury|Acute Respiratory Distress Syndrome |
None |